VCM
FTH

Vanguard Capital Management’s Faeth Therapeutics FTH Stock Holding History

Vanguard Capital Management’s Portfolio FTH Stock Details FTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$244K Buy
+7,750
New +$155K ﹤0.01% 3773

Other funds holding FTH

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
SC
Stempoint Capital New York $522M AUM 281.95% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

Vanguard Capital Management's FTH Position: Q1 2026 in Review

Vanguard Capital Management opened a new position in Faeth Therapeutics (FTH) in Q1 2026: 7,750 shares worth $244K. The stake represents ﹤0.01% of the portfolio and ranks #3773 among its holdings.

30 funds tracked by Wall St. Rank hold FTH as of Q1 2026.

  • Vanguard Capital Management held 7,750 shares of Faeth Therapeutics worth $244K as of Q1 2026.
  • Faeth Therapeutics was a new Vanguard Capital Management position in Q1 2026.
  • Faeth Therapeutics made up ﹤0.01% of Vanguard Capital Management's portfolio in Q1 2026, its #3773 holding.
  • 30 funds tracked by Wall St. Rank held Faeth Therapeutics as of Q1 2026.

Based on Vanguard Capital Management's 13F filing for Q1 2026, filed 8 May 2026.